Plasma total cell-free DNA (cfDNA) is a surrogate biomarker for tumour burden and a prognostic biomarker for survival in metastatic melanoma patients

por Valpione, S., Gremel, G., Mundra, P., Middlehurst, P., Galvani, E., Girotti, M.R., Lee, R.J., Garner, G., Dhomen, N., Lorigan, P.C., Marais, R.
Publicado 2018

Circulating tumor DNA predicts survival in patients with resected high-risk stage II/III melanoma

por Lee, R J, Gremel, G, Marshall, A, Myers, K A, Fisher, N, Dunn, J A, Dhomen, N, Corrie, P G, Middleton, M R, Lorigan, P, Marais, R
Publicado 2018

Functional and prognostic relevance of the homeobox protein MSX2 in malignant melanoma

por Gremel, G, Ryan, D, Rafferty, M, Lanigan, F, Hegarty, S, Lavelle, M, Murphy, I, Unwin, L, Joyce, C, Faller, W, McDermott, E W, Sheahan, K, Ponten, F, Gallagher, W M
Publicado 2011

Distinct subclonal tumour responses to therapy revealed by circulating cell-free DNA

por Gremel, G., Lee, R. J., Girotti, M. R., Mandal, A. K., Valpione, S., Garner, G., Ayub, M., Wood, S., Rothwell, D. G., Fusi, A., Wallace, A., Brady, G., Dive, C., Dhomen, N., Lorigan, P., Marais, R.
Publicado 2016